Pediatric Nephrology

, Volume 23, Issue 4, pp 559–567 | Cite as

Development of an experimental hemolytic uremic syndrome in rats

  • Elsa Zotta
  • Nestor Lago
  • Federico Ochoa
  • Horacio A. Repetto
  • Cristina IbarraEmail author
Original Article


Escherichia coli strains producing Shiga toxins (Stxs) colonize the lower gastrointestinal tract and cause watery diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome (HUS). HUS is characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. Oliguria associated with acute tubular necrosis and microangiopathic thrombosis has been reported as the most common cause of renal failure in Argentinean children. Our study was undertaken to obtain a model of HUS in rats that was similar to the clinical and renal histopathology findings described in humans. Rats were intraperitoneally inoculated with culture supernatant from recombinant E. coli expressing Stx2. Glomerular filtrate volume evaluated from clearance of creatinine resulted in a progressive reduction (from 53% at 24 h to 90% at 48 h). Urine volume increased significantly at 24 h but returned to normal levels at 48 h. Evidence of thrombocytopenia, anemia and leukocytosis was documented. Macroscopic analysis revealed a hyperemic peritoneal face with intestinal water accumulation. The kidneys were friable and congestive. Histopathological analysis showed glomerular and tubular necrosis as well as microangiopathic thrombosis. Our findings indicated vascular damage and kidney lesions similar to those described in humans with HUS.


Hemolytic uremic syndrome Acute tubular necrosis Thrombotic microangiopathy Shiga toxin Diarrhea 



This paper was presented at the 50th Annual Scientific Meeting, Argentine Society of Clinical Investigation (SAIC), Mar del Plata, Argentina, 29th November to 2nd December, 2005, and the 6th International Symposium on Shiga toxin (Verocytotoxin-producing Escherichia coli infection, Melbourne, Australia, 29th October to 1st November, 2006. This work was supported by the University of Buenos Aires (M038, M827), the National Council of Research (CONICET, PIP 5587) and ANPCYT (PICT-26224). The authors gratefully acknowledge Claudio Mirabelli for his excellent technical assistance.


  1. 1.
    Griffin PM, Tauxe RV (1991) The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 13:60–98PubMedGoogle Scholar
  2. 2.
    Remuzzi G, Ruggenenti P (1995) The hemolytic uremic syndrome. Kidney Int 48:2–19CrossRefGoogle Scholar
  3. 3.
    Repetto HA (1997) Epidemic hemolytic-uremic syndrome in children. Nephrology Forum. Kidney Int 52:1708–1719CrossRefGoogle Scholar
  4. 4.
    Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR (1997) Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 11:156–160CrossRefGoogle Scholar
  5. 5.
    Robson WL, Leung AK, Brant R (1993) Relationship of the recovery in the glomerular filtration rate to the duration of anuria in diarrhea-associated hemolytic uremic syndrome. Am J Nephrol 13:194–197CrossRefGoogle Scholar
  6. 6.
    Tonshoff B, Sammet A, Sanden I, Mehls O, Waldherr R, Scharer K (1994) Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron 68:63–70CrossRefGoogle Scholar
  7. 7.
    Scully RE, Mark EJ, McNeely WF, Ebeling SH, Phillips LD (1995) Case records of the Massachusetts General Hospital. N Engl J Med 336:1587–1594Google Scholar
  8. 8.
    Tarr PI (1995) Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin Infect Dis 20:1–8CrossRefGoogle Scholar
  9. 9.
    Lopez EL, Diaz M, Grinstein S, Devoto S, Mendilaharzu F, Murray BE, Ashkenazi S, Rubeglio E, Woloj M, Vasquez M, Turco M, Pickering LK, Cleary TG (1989) Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis 160:469–475CrossRefGoogle Scholar
  10. 10.
    Rivas M, Balbi L, Miliwebsky ES, Garcia B, Tous MI, Leardini NA, Prieto MA, Chillemi GM, De Principi ME (1998) Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga-toxin producing Escherichia coli infection. Medicina (B. Aires) 58:1–7Google Scholar
  11. 11.
    Rivas M, Caletti MG, Chinen I, Refi SM, Roldan CD, Chillemi G, Fiorilli G, Bertolotti A, Aguerre L, Estani SS (2003) Home-prepared hamburger and sporadic hemolytic uremic syndrome, Argentina. Emerg Infect Dis 9:1184–1186CrossRefGoogle Scholar
  12. 12.
    Rivas M, Milwebsky E, Chinen I, Deza N, Leotta G (2006) The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission. Medicina (B. Aires) 66:27–32Google Scholar
  13. 13.
    Exeni R (2001) Síndrome Urémico Hemolítico. Arch Latin Nefr Ped 1:35–56Google Scholar
  14. 14.
    Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, O’Brien AD, Samuel JE (1993) Comparison of the relative toxicities of Shiga-like toxins type 1 and type 2 for mice. Infect Immun 61:3392–3402PubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhao YL, Cen XB, Ito M, Yokoyama K, Takagi K, Kitaichi K, Nadai M, Ohta M, Takagi K, Hasegawa T (2002) Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats. Antimicrob Agents Chemother 46:1522–1528CrossRefGoogle Scholar
  16. 16.
    Sugatani J, Komiyama N, Mochizuki T, Hoshino M (2002) Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria. Life Sci 71:171–189CrossRefGoogle Scholar
  17. 17.
    Keepers T, Psotka M, Gross L, Obrig T (2006) A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 17:3404–3414CrossRefGoogle Scholar
  18. 18.
    Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C (1997) The role of lipopolysaccharide and Shiga like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 175:611–620CrossRefGoogle Scholar
  19. 19.
    Siegler Rl, Pysher TJ, Lou R, Tesh VL, Taylor FB Jr (2001) Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Am J Nephrol 21:420–425CrossRefGoogle Scholar
  20. 20.
    Palermo M, Alves-Rosa F, Rubel C, Fernandez GC, Fernandez- Alonso G, Alberto F, Rivas M, Isturiz M (2000) Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose dependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol 119:77–83CrossRefGoogle Scholar
  21. 21.
    Louise C, Obrig T (1992) Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 60:1536–1543PubMedPubMedCentralGoogle Scholar
  22. 22.
    Duner KI (1993) A new kinetic single stage Limulus amoebocyte lysate method for the detection of endotoxin in water and plasma. J Biochem Biophys Methods 26:131–142CrossRefGoogle Scholar
  23. 23.
    Fujii J, Kinoshita Y, Yutsudo T, Taniguchi H, Obrig T, Yoshida SI (2001) Toxicity of Shiga toxin 1 in the central nervous system of rabbits. Infect Immun 69:6545–6548CrossRefGoogle Scholar
  24. 24.
    Pistone Creydt V, Silberstein C, Zotta E, Ibarra C (2006) Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells. Microbes Infect 8:410–419CrossRefGoogle Scholar
  25. 25.
    Pistone Creydt V, Miyakawa MF, Martin F, Zotta E, Silberstein C, Ibarra C (2004) The Shiga toxin 2B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Braz J Med Biol Res 37:799–808CrossRefGoogle Scholar
  26. 26.
    Dean-Nystrom EA, Melton-Celsa AR, Pohlenz JF, Moon HW, O’Brien AD (2003) Comparative pathogenicity of Escherichia coli O157 and intimin-negative non-O157 Shiga toxin-producing E. coli strains in neonatal pigs. Infect Immun 71:6526–6533CrossRefGoogle Scholar
  27. 27.
    Gunzer F, Hennig-Pauka I, Waldmann KH, Sandhoff R, Grone HJ, Kreipe HH, Matussek A, Mengel M (2002) Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. Am J Clin Pathol 118:364–375CrossRefGoogle Scholar
  28. 28.
    Imai Y, Fukui T, Kurohane K, Miyamoto D, Suzuki Y, Ishikawa T, Ono Y, Miyake M (2003) Restricted expression of Shiga toxin binding sites on mucosal epithelium of mouse distal colon. Infect Immun 71:985–990CrossRefGoogle Scholar
  29. 29.
    Pruimboom-Brees I, Morgan T, Ackermann M, Nystrom E, Samuel J, Cornick N, Moon H (2000) Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins. Proc Natl Acad Sci USA 97:10325–10329CrossRefGoogle Scholar
  30. 30.
    Taylor FB Jr, Tesh VL, DeBault L, Li A, Chang AC, Kosanke SD, Pysher TJ, Siegler RL (1999) Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154:1285–1299CrossRefGoogle Scholar
  31. 31.
    Pohlenz JF, Winter KR, Dean-Nystrom EA (2005) Shiga-toxigenic Escherichia coli-inoculated neonatal piglets develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome. Infect Immun 73:612–616CrossRefGoogle Scholar
  32. 32.
    Rutjes N, Binnington B, Smith C, Maloney M, Lingwood L (2002) Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 62:832–845CrossRefGoogle Scholar
  33. 33.
    Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60:831–846CrossRefGoogle Scholar
  34. 34.
    Richardson SE, Karmali MA, Becker LE, Smith CR (1988) The histopathology of the hemolytic uremic syndrome (HUS) associated with verocytotoxin producing Escherichia coli infections. Hum Pathol 19:1102–1108CrossRefGoogle Scholar
  35. 35.
    Kato G, McGowan V, Machado R, Little J, Taylor J VI, Morris C, Nichols J, Wang X, Poljakovic M, Morris Jr S, Gladwin M (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107:2279–2285CrossRefGoogle Scholar
  36. 36.
    Brain MC (1970) Microangiopathic hemolytic anemia. Annu Rev Med 21:133–144CrossRefGoogle Scholar
  37. 37.
    Donato H, Rendo P, Exeni R, Rapetti MC, Antonuccio M, Galvagni A, Grimoldi I, Exeni A (1997) Erythropoietin deficiency in children with acute renal insufficiency due to hemolytic uremic syndrome. Hematología (B. Aires) 1:5–11Google Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  • Elsa Zotta
    • 1
  • Nestor Lago
    • 2
  • Federico Ochoa
    • 1
  • Horacio A. Repetto
    • 3
  • Cristina Ibarra
    • 1
    • 4
    Email author
  1. 1.Laboratorio de Fisiopatogenia, Depto de Fisiología, Facultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
  2. 2.Laboratorio de Patología Experimental, Depto de Patología, Facultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
  3. 3.Servicio de Pediatría, Hospital Nacional Prof. Alejandro PosadasBuenos AiresArgentina
  4. 4.Depto de Fisiología, Facultad de MedicinaBuenos AiresArgentina

Personalised recommendations